# GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Canonical URL: https://biopharmsignal.com/news/GNFT/genfit-reports-full-year-2025-financial-results-and-provides-corporate-update
Ticker: GNFT
Company: GENFIT
Source: GENFIT
Published: 2026-04-02 16:30 EST
Original Source URL: https://ir.genfit.com
## Summary

2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen Cash runway beyond the end of 2028 2026 business

## Article Body
2025 financial highlights: Cash and cash equivalents totaled €101.1 million as of December 31, 2025 Revenues amounting to €65.4 million for the period ended December 31, 2025, including €43.6 million in milestones and €21.8 in royalties from Ipsen Cash runway beyond the end of 2028 2026 business
## Recent Company News
- 2026-07-08 16:00 EST — [Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial](https://biopharmsignal.com/news/GNFT/genfit-half-year-report-of-liquidity-contract-with-cr-dit-industriel-et-commerci-c386698c) — Source: GENFIT
- 2026-07-02 16:05 EST — [GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH](https://biopharmsignal.com/news/GNFT/genfit-announces-u-s-medicare-coverage-and-future-reimbursement-for-nashnext-a-n-2769741e) — Source: GENFIT
- 2026-06-23 16:00 EST — [GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma](https://biopharmsignal.com/news/GNFT/genfit-positive-phase-1b-data-with-gns561-in-combination-therapy-in-heavily-pret-b018e66c) — Source: GENFIT
- 2026-06-15 16:10 EST — [GENFIT: June 15, 2026 Combined Shareholders Meeting Results](https://biopharmsignal.com/news/GNFT/genfit-june-15-2026-combined-shareholders-meeting-results-d07ad996) — Source: GENFIT
- 2026-06-08 16:00 EST — [GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp’s OnDemand Offering for Identification of At-Risk MASH](https://biopharmsignal.com/news/GNFT/genfit-nashnext-powered-by-genfit-s-non-invasive-diagnostic-technology-nis4-laun-bff6954d) — Source: GENFIT
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)